New Global Industry Coalition Aims to Dramatically Increase Access for All Patients Populations in Clinical Trials and Research
December 23, 2020 – xCures joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized Trials & Research Alliance (DTRA),” which launched December 10th, 2020, plans to unite industry stakeholders, including healthcare companies, regulators, patient groups, and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
“xCures is pleased to become a founding member of the Alliance. It enables new levels of collaboration and partnering to put patients first,” said Mika Newton, CEO of xCures. “Prospective patient-centric decentralized trials and generating regulatory grade real-world evidence are playing an ever more important role in both development and commercialization of cancer therapies.”
“We are extremely gratified to welcome xCures to the ‘Decentralized Trials & Research Alliance,’ said Amir Kalali, MD, founder of several collaborative life science communities and co-convenor of DTRA. “By advancing decentralized research, we can make the clinical trial process more patient-focused, increase trial efficiency, and encourage the use of technologies. We are excited by xCures commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”
Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age, and geographic location has long been an operational challenge. COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants.
“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives – and by taking part in the DTRA, xCures is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-convener, clinical innovation advisor, and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders, and patient communities, we can remove remaining barriers to adoption and impact patients today.”
xCures joins with its peer DTRA Member organizations to provide expertise to identify and address gaps and needs and advance best practices through effective education and communication. (Member Organization) urges other organizations interested in taking part to visit DTRA.org
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.
xCures Inc. operates an AI-assisted clinical platform that connects cancer patients and physicians with optimal investigational or approved therapies. The platform prospectively generates real-world evidence for clinical studies, expanded access programs, and decentralized trials. For more information, visit www.xcures.com and or contact firstname.lastname@example.org.
# # #
For further information, please contact:
Lazar – Finn Partners
646 871 8485